162 related articles for article (PubMed ID: 19747734)
1. Humanized cobra venom factor decreases myocardial ischemia-reperfusion injury.
Gorsuch WB; Guikema BJ; Fritzinger DC; Vogel CW; Stahl GL
Mol Immunol; 2009 Dec; 47(2-3):506-10. PubMed ID: 19747734
[TBL] [Abstract][Full Text] [Related]
2. Identification of functionally important amino acid sequences in cobra venom factor using human C3/Cobra venom factor hybrid proteins.
Hew BE; Fritzinger DC; Pangburn MK; Vogel CW
Toxicon; 2019 Sep; 167():106-116. PubMed ID: 31207349
[TBL] [Abstract][Full Text] [Related]
3. Structure and function of recombinant cobra venom factor.
Kock MA; Hew BE; Bammert H; Fritzinger DC; Vogel CW
J Biol Chem; 2004 Jul; 279(29):30836-43. PubMed ID: 15131128
[TBL] [Abstract][Full Text] [Related]
4. Hybrid proteins of Cobra Venom Factor and cobra C3: tools to identify functionally important regions in Cobra Venom Factor.
Hew BE; Wehrhahn D; Fritzinger DC; Vogel CW
Toxicon; 2012 Sep; 60(4):632-47. PubMed ID: 22609532
[TBL] [Abstract][Full Text] [Related]
5. Recombinant cobra venom factor.
Vogel CW; Fritzinger DC; Hew BE; Thorne M; Bammert H
Mol Immunol; 2004 Jun; 41(2-3):191-9. PubMed ID: 15159065
[TBL] [Abstract][Full Text] [Related]
6. Absence of a neutralizing antibody response to humanized cobra venom factor in mice.
Ing M; Hew BE; Fritzinger DC; Delignat S; Lacroix-Desmazes S; Vogel CW; Rayes J
Mol Immunol; 2018 May; 97():1-7. PubMed ID: 29525557
[TBL] [Abstract][Full Text] [Related]
7. Cobra venom factor: Structure, function, and humanization for therapeutic complement depletion.
Vogel CW; Fritzinger DC
Toxicon; 2010 Dec; 56(7):1198-222. PubMed ID: 20417224
[TBL] [Abstract][Full Text] [Related]
8. Identification of intermolecular bonds between human factor B and Cobra Venom Factor important for C3 convertase stability.
Hew BE; Pangburn MK; Vogel CW; Fritzinger DC
Toxicon; 2020 Sep; 184():68-77. PubMed ID: 32526239
[TBL] [Abstract][Full Text] [Related]
9. Functional characterization of human C3/cobra venom factor hybrid proteins for therapeutic complement depletion.
Fritzinger DC; Hew BE; Thorne M; Pangburn MK; Janssen BJ; Gros P; Vogel CW
Dev Comp Immunol; 2009; 33(1):105-16. PubMed ID: 18760301
[TBL] [Abstract][Full Text] [Related]
10. Complement and myoblast transfer therapy: donor myoblast survival is enhanced following depletion of host complement C3 using cobra venom factor, but not in the absence of C5.
Hodgetts SI; Grounds MD
Immunol Cell Biol; 2001 Jun; 79(3):231-9. PubMed ID: 11380675
[TBL] [Abstract][Full Text] [Related]
11. Complement depletion with humanized cobra venom factor in a mouse model of age-related macular degeneration.
Fritzinger DC; Dean R; Meschter C; Wong K; Halter R; Borlak J; St John WD; Vogel CW
Adv Exp Med Biol; 2010; 703():151-62. PubMed ID: 20711713
[TBL] [Abstract][Full Text] [Related]
12. Derivatives of human complement component C3 for therapeutic complement depletion: a novel class of therapeutic agents.
Fritzinger DC; Hew BE; Lee JQ; Newhouse J; Alam M; Ciallella JR; Bowers M; Gorsuch WB; Guikema BJ; Stahl GL; Vogel CW
Adv Exp Med Biol; 2008; 632():293-307. PubMed ID: 19025130
[TBL] [Abstract][Full Text] [Related]
13. Humanized cobra venom factor: experimental therapeutics for targeted complement activation and complement depletion.
Vogel CW; Fritzinger DC
Curr Pharm Des; 2007; 13(28):2916-26. PubMed ID: 17979736
[TBL] [Abstract][Full Text] [Related]
14. The cobra complement system: I. The alternative pathway of activation.
Vogel CW; Müller-Eberhard HJ
Dev Comp Immunol; 1985; 9(2):311-25. PubMed ID: 3894085
[TBL] [Abstract][Full Text] [Related]
15. Humanized cobra venom factor: structure, activity, and therapeutic efficacy in preclinical disease models.
Vogel CW; Finnegan PW; Fritzinger DC
Mol Immunol; 2014 Oct; 61(2):191-203. PubMed ID: 25062833
[TBL] [Abstract][Full Text] [Related]
16. Antigenic relationships between human and cobra complement factors C3 and cobra venom factor (CVF) from the Indian cobra (Naja naja).
Eggertsen G; Lundwall A; Hellman U; Sjöquist J
J Immunol; 1983 Oct; 131(4):1920-3. PubMed ID: 6194220
[TBL] [Abstract][Full Text] [Related]
17. Methionine modification impairs the C5-cleavage function of cobra venom factor-dependent C3/C5 convertase.
Fu Q; McPhie P; Gowda DC
Biochem Mol Biol Int; 1998 Jun; 45(1):133-44. PubMed ID: 9635137
[TBL] [Abstract][Full Text] [Related]
18. Role of the complement components C5 and C3a in a mouse model of myocardial ischemia and reperfusion injury.
Busche MN; Stahl GL
Ger Med Sci; 2010 Sep; 8():. PubMed ID: 20930931
[TBL] [Abstract][Full Text] [Related]
19. Complement and neutrophil activation in the pathogenesis of ischemic myocardial injury.
Crawford MH; Grover FL; Kolb WP; McMahan CA; O'Rourke RA; McManus LM; Pinckard RN
Circulation; 1988 Dec; 78(6):1449-58. PubMed ID: 3191598
[TBL] [Abstract][Full Text] [Related]
20. Functional analysis of Cobra Venom Factor/human C3 chimeras transiently expressed in mammalian cells.
Kölln J; Matzas M; Jänner N; Mix T; Klensang K; Bredehorst R; Spillner E
Mol Immunol; 2004 May; 41(1):19-28. PubMed ID: 15140572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]